1. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). (23rd February 2019) Authors: Bachelot, T; Ciruelos, E; Schneeweiss, A; Puglisi, F; Peretz-Yablonski, T; Bondarenko, I; Paluch-Shimon, S; Wardley, A; Merot, J -L; du Toit, Y; Easton, V; Lindegger, N; Miles, D Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 766 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗